Skip to main content

Advertisement

Table 5 Number of participants reporting adverse events by body system

From: A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo

Body system category Total Placebo NAC CT
(N = 181) n = 61 n = 59 n = 61
Behavioural 38% (68) 33% (20) 34% (20) 44% (27)
Gastrointestinal 56% (101) 41% (25) 69% (41)* 57% (35)
Musculoskeletal 13% (24) 13% (8) 19% (11) 8% (5)
Neurological 17% (31) 23% (14) 10% (6) 18% (11)
Respiratory 34% (61) 39% (24) 36% (21) 26% (16)
Other 34% (62) 46% (28) 34% (20) 23% (14)*
  1. Note: NAC, N-acetylcysteine; CT, combination nutraceutical treatment. * Significantly different from the placebo, all other comparisons ns